




Instance: composition-en-dbc2060ee6f62aba124d52b5666f8915
InstanceOf: CompositionUvEpi
Title: "Composition for lytgobi Package Leaflet"
Description:  "Composition for lytgobi Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp78f306f1e92f048feb21539cfb100a4b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - lytgobi"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Lytgobi is and what it is used for  </li>
<li>What you need to know before you take Lytgobi </li>
<li>How to take Lytgobi </li>
<li>Possible side effects  </li>
<li>How to store Lytgobi </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What lytgobi is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What lytgobi is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lytgobi contains the active substance futibatinib, which belongs to a group of cancer medicines called 
tyrosine kinase inhibitors. It blocks the action of a protein in the cell, called fibroblast growth factor 
receptor (FGFR), that helps regulate cell growth. Cancer cells may have an abnormal form of this 
protein. By blocking FGFR, futibatinib can prevent the growth of such cancer cells. </p>
<p>Lytgobi is used on its own (monotherapy)to treat adults with bile duct cancer (also known as 
cholangiocarcinoma) that has spread or cannot be removed by surgery in patients who have already 
received previous treatment, and whose tumour has a certain type of abnormal  FGFR . </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take lytgobi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take lytgobi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Lytgobi if you are allergic to futibatinib or any of the other ingredients of this medicine 
(listed in section 6). </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Lytgobi if you have: 
* been told you have high levels of phosphate in your blood (a condition known as 
hyperphosphataemia) based on a blood test result 
* vision or eye problems such as problems with the retina (light-sensitive layers of nerve tissue at 
the back of the eye) </p>
<p>Eye examinations are recommended: 
* before starting treatment with Lytgobi 
* 6 weeks thereafter or at any time if any visual or eye problems occur.  </p>
<p>Lytgobi can cause serous retinal detachment (retina pulls away from its normal position). Symptoms 
include blurred vision, flashes of light in the field of vision (photopsia) and small dark shapes moving 
in the field of vision (floaters). Tell your doctor straight away if you get any problems with your 
vision. </p>
<p>Lytgobi can cause high levels of phosphate in your blood and may lead to a build-up of minerals such 
as calcium in different tissues in your body. Your doctor may prescribe changes in your diet, 
phosphate lowering therapy, or change or stop treatment with Lytgobi if needed. Tell your doctor 
straight away if you develop painful skin lesions, any muscle cramps, numbness or tingling around 
your mouth, or an abnormal heartbeat.    </p>
<p>Lytgobi may harm the unborn baby. If you are a woman of childbearing age or your partner is of 
childbearing capacity, you must use an effective contraception during treatment and for 1 week after 
the last dose of Lytgobi. Because it is not known if Lytgobi decreases the effectiveness of birth 
control medication, barrier methods should be applied in addition to such medication to avoid 
pregnancy. </p>
<p>Children and adolescents </p>
<p>Lytgobi should not be given to children or adolescents under 18 years. It is not known whether it is 
safe and effective in this age group. </p>
<p>Other medicines and Lytgobi 
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other 
medicines. </p>
<p>In particular, you should tell your doctor if you are taking any of the following medicines so that the 
doctor can decide if your treatment needs to change: 
* itraconazole: a medicine to treat fungal infections<br />
<em> clarithromycin: medicines to treat certain infections 
* rifampicin: a medicine to treat tuberculosis or certain other infections<br />
</em> carbamazepine, phenytoin, phenobarbital: medicines to treat epilepsy<br />
<em> efavirenz: medicine to treat HIV infection<br />
</em> digoxin: a medicine to treat heart disease<br />
<em> dabigatran: a medicine to prevent blood clots<br />
</em> colchicine: a medicine to treat gout attacks 
* rosuvastatin: a medicine to treat high cholesterol<br />
* theophylline: a medicine to treat breathing problems 
* olanzapine: a medicine to manage symptoms of mental health conditions </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<ul>
<li>Pregnancy /Contraception -information for women 
You should not become pregnant during the treatment with Lytgobi because this medicine could 
harm your baby. A pregnancy test should be performed before initiating treatment, and women 
who could become pregnant must use effective contraception during treatment and for 1 week 
after the last dose of Lytgobi. Barrier methods should be applied as a second form of 
contraception to avoid pregnancy. Talk to your doctor about the most suitable contraception for 
you. </li>
<li>Contraception -information for men<br />
You should not conceive a child during treatment with Lytgobi because this medicine may harm 
the baby. You must use effective contraception during treatment and for 1 week after the last dose 
of Lytgobi.  </li>
<li>Breast-feeding 
Do not breast-feed during treatment with Lytgobi and for 1 week after the last dose. This is </li>
</ul>
<p>because it is not known if Lytgobi can pass into breast milk and could therefore harm your baby. 
Driving and using machines 
Lytgobi can cause side effects such as fatigue or visual disturbances. Do not drive or operate 
machinery if this happens. </p>
<p>Lytgobi contains lactose and sodium 
This medicine contains lactose (found in milk or dairy products). If you have been told by your doctor 
that you have an intolerance to some sugars, contact your doctor before taking this medicine. 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take lytgobi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take lytgobi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lytgobi treatment should be started by a doctor who is experienced in the diagnosis and treatment of 
bile duct cancer. Always take this medicine exactly as your doctor or pharmacist has told you. Check 
with your doctor or pharmacist if you are not sure.  </p>
<p>The recommended dose is 
5 tablets of Lytgobi 4 mg (20 mg futibatinib in total) taken orally once daily. Your doctor will adjust 
the dose or stop treatment if needed. </p>
<p>Method of administration 
Swallow the tablet whole with one glass of water at the same time every day. Lytgobi may be taken 
with food or between meals. The tablets should be swallowed whole to ensure that the full dose is 
taken.  </p>
<p>Duration of treatment 
Take Lytgobi for as long as it is prescribed by the doctor. </p>
<p>If you take more Lytgobi than you should 
Tell your doctor straight away if you have taken more Lytgobi than you should have. </p>
<p>If you forget to take Lytgobi 
* If you miss a dose of Lytgobi by 12 hours or less, take the missed dose as soon as you remember. 
* If you miss a dose of Lytgobi by more than 12 hours, skip the missed dose. Take your next dose at 
the usual time. 
* Do not take a double dose of Lytgobi if you experience vomiting. Take the next dose at your 
scheduled usual time. 
* Do not take a double dose to make up for a missed dose. </p>
<p>If you stop taking Lytgobi 
Do not stop taking Lytgobi without discussing it with your doctor, as stopping treatment could reduce 
the success of therapy. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>If you have any of the serious side effects below, tell your doctor immediately. These side effects 
listed below are common (may affect up to 1 in 10 people). 
* Migraine 
* Intestinal obstruction </p>
<p>Other side effects<br />
Talk to your doctor if you get any other side effects. These may occur with the following frequencies: </p>
<p>Very common (may affect more than 1 in 10 people) 
* high or low phosphate levels seen in blood tests 
* low sodium levels seen in blood tests 
* nails separating from the nail bed, poor formation of the nail, change in colour of the nails 
* constipation 
* diarrhoea 
* dry mouth 
* vomiting 
* abdominal pain 
* hair loss (alopecia) 
* feeling tired or weak 
* dry skin 
* high levels of liver enzyme seen in blood tests 
* nausea 
* inflammation of the lining of the mouth (stomatitis) 
* decreased appetite 
* dry eye 
* redness, swelling, peeling or tenderness, mainly on the hands or feet ( hand-foot  syndrome) 
* change in sense of taste 
* muscle pain 
* joint pain </p>
<p>Common (may affect up to 1 in 10 people) 
* Eye problems including inflammation of the eyes or cornea (front part of the eye), blurred vision, 
sudden appearance of small dark shapes moving in the field of vision (floaters) and flashes of 
light in the field of vision (photopsia).  </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store lytgobi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store lytgobi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Lytgobi contains<br />
* The active substance is futibatinib.<br />
Each film-coated tablet contains 4 mg futibatinib.  </p>
<ul>
<li>The other ingredient(s) are: </li>
</ul>
<p>Tablet core: maize starch, crospovidone, hydroxypropylcellulose, lactose monohydrate, 
magnesium stearate, mannitol, cellulose microcrystalline and sodium lauril sulfate (see section 2, 
 Lytgobi contains lactose and sodium )<br />
Film coating: hypromellose, macrogols, and titanium dioxide<br />
Lustering agent: magnesium stearate </p>
<p>What Lytgobi looks like and contents of the pack 
Lytgobi 4 mg is supplied as round, white, film-coated tablets, debossed on one side with  4MG  and 
 FBN  on the other side. </p>
<p>Lytgobi tablets are packaged in a blister card sealed inside a folding wallet containing a 7-day supply 
as follows: 
* 20 mg daily dose: Each wallet contains 35 tablets (5 tablets once daily). <br />
<em> 16 mg daily dose: Each wallet contains 28 tablets(4 tablets once daily). <br />
</em> 12 mg daily dose: Each wallet contains 21 tablets (3 tablets once daily).    </p>
<p>Marketing Authorisation Holder 
Taiho Pharma Netherlands B.V. 
Barbara Strozzilaan 1083HN Amsterdam 
Netherlands </p>
<p>Manufacturer 
PCI Pharma Services (Millmount Healthcare Limited) 
Block 7, City North Business Campus 
Stamullen, Co. Meath, K32 YDIreland </p>
<p>This leaflet was last revised in {MM/YYYY} 
This medicine has been given  conditional approval .<br />
This means that there is more evidence to come about this medicine. 
The European Medicines Agency will review new information on this medicine at least every year 
and this leaflet will be updated as necessary. </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu. </p>
<p>This leaflet is available in all EU/EEA languages on the European Medicines Agency website. </p>         </div>"""      



Instance: composition-da-dbc2060ee6f62aba124d52b5666f8915
InstanceOf: CompositionUvEpi
Title: "Composition for lytgobi Package Leaflet"
Description:  "Composition for lytgobi Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp78f306f1e92f048feb21539cfb100a4b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - lytgobi"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du begynder at tage Lytgobi </li>
<li>Sådan skal du tage Lytgobi </li>
<li>Bivirkninger  </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What lytgobi is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What lytgobi is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lytgobi indeholder det aktive stof futibatinib, som tilhører en gruppe kræftlægemidler kaldet 
tyrosinkinasehæmmere. Det blokerer virkningen af et protein i cellen kaldet 
fibroblastvækstfaktorreceptor, som hjælper med at regulere cellevækst. Kræftceller kan have en 
unormal form af dette protein. Ved at blokere FGFR kan futibatinib forhindre væksten af sådanne 
kræftceller. </p>
<p>Lytgobi anvendes alene (monoterapi) til behandling af voksne med galdegangskræft (også kendt som 
cholangiocarcinom), der har spredt sig eller ikke kan fjernes ved operation hos patienter, der allerede 
har modtaget tidligere behandling, og hvis tumor har en bestemt type unormal "FGFR". </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take lytgobi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take lytgobi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Lytgobi hvis du er allergisk over for futibatinib eller et af de øvrige indholdsstoffer i dette 
lægemiddel (angivet i punkt 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Lytgobi, hvis du har: </p>
<ul>
<li>
<p>fået at vide, at du har høje niveauer af fosfat i blodet (en tilstand, der kaldes hyperfosfatæmi) 
baseret på et blodprøveresultat </p>
</li>
<li>
<p>syns- eller øjenproblemer, såsom problemer med nethinden (lysfølsomme lag af nervevæv bagerst 
i øjet) </p>
</li>
</ul>
<p>Øjenundersøgelser anbefales: </p>
<ul>
<li>
<p>før påbegyndelse af behandling med Lytgobi </p>
</li>
<li>
<p>6 uger derefter eller når som helst, hvis der opstår syns- eller øjenproblemer.  </p>
</li>
</ul>
<p>Lytgobi kan forårsage serøs nethindeløsning (nethinden trækker sig væk fra sin normale position). 
Symptomerne omfatter sløret syn, lysglimt i synsfeltet (fotopsi) og små mørke former, der bevæger 
sig i synsfeltet (flydere). Fortæl straks din læge, hvis du får problemer, der involverer dit syn. </p>
<p>Lytgobi kan forårsage høje niveauer af fosfat i blodet og kan føre til en ophobning af mineraler såsom 
kalcium i forskellige væv i kroppen. Lægen kan ordinere ændringer i din kost, fosfatsænkende 
behandling eller ændre eller stoppe behandlingen med Lytgobi, hvis det er nødvendigt. Fortæl det 
straks til lægen, hvis du udvikler smertefulde hudlæsioner, muskelkramper, følelsesløshed eller 
snurren omkring munden eller unormal hjerterytme. </p>
<p>Lytgobi kan skade det ufødte barn. Hvis du er en kvinde i den fertile alder eller hvis din partner er 
fødedygtig, skal du anvende en effektiv præventionsmetode under behandlingen og i 1 uge efter den 
sidste dosis Lytgobi. Fordi det ikke vides, om Lytgobi nedsætter virkningen af præventionsmidler, bør 
barrieremetoder anvendes ud over et sådant middel for at undgå graviditet. </p>
<p>Børn og unge </p>
<p>Lytgobi må ikke gives til børn eller unge under 18 år. Det vides ikke, om det er sikkert og effektivt i 
denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med Lytgobi 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget 
andre lægemidler eller planlægger at tage andre lægemidler. </p>
<p>Du skal især fortælle din læge, hvis du tager nogen af følgende lægemidler, så lægen kan beslutte, om 
din behandling skal ændres: </p>
<ul>
<li>
<p>Itraconazol: et lægemiddel til behandling af svampeinfektioner.  </p>
</li>
<li>
<p>Clarithromycin: lægemidler til behandling af visse infektioner </p>
</li>
<li>
<p>Rifampicin: et lægemiddel til behandling af tuberkulose eller visse andre infektioner.  </p>
</li>
<li>
<p>Carbamazepin, fenytoin, fenobarbital: lægemidler til behandling af epilepsi  </p>
</li>
<li>
<p>Efavirenz: lægemiddel til behandling af hiv-infektion.  </p>
</li>
<li>
<p>Digoxin: et lægemiddel til behandling af hjertesygdomme.  </p>
</li>
<li>
<p>Dabigatran: et lægemiddel til forebyggelse af blodpropper.  </p>
</li>
<li>
<p>Colchicin: et lægemiddel til behandling af podagraanfald. </p>
</li>
<li>
<p>Rosuvastatin: et lægemiddel til behandling af højt kolesteroltal  </p>
</li>
<li>
<p>Teofyllin: et lægemiddel til behandling af vejrtrækningsproblemer </p>
</li>
<li>
<p>Olanzapin: et lægemiddel til håndtering af symptomer på psykiske sygdomme </p>
</li>
</ul>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<ul>
<li>
<p>Graviditet/prævention - information til kvinder 
Du må ikke blive gravid under behandlingen med Lytgobi, da dette lægemiddel kan skade dit 
barn. Der skal udføres en graviditetstest, før behandlingen påbegyndes, og kvinder, der kan blive 
gravide, skal bruge effektiv prævention under behandlingen og i 1 uge efter den sidste dosis 
Lytgobi. Der skal anvendes barrieremetoder som endnu en form for prævention for at undgå 
graviditet. Tal med din læge om den prævention, der passer bedst til dig. </p>
</li>
<li>
<p>Prævention - information til mænd  </p>
</li>
</ul>
<p>Du må ikke undfange et barn under behandling med Lytgobi, fordi dette lægemiddel kan skade 
barnet. Du skal bruge effektiv prævention under behandlingen og i 1 uge efter den sidste dosis af 
Lytgobi.  </p>
<ul>
<li>Amning 
Undlad at amme under behandling med Lytgobi og i 1 uge efter den sidste dosis. Dette skyldes, at 
det ikke vides, om Lytgobi kan passere over i modermælken og derfor kan skade din baby. </li>
</ul>
<p>Trafik- og arbejdssikkerhed 
Lytgobi kan forårsage bivirkninger som f.eks. træthed eller synsforstyrrelser. Undlad at køre bil eller 
betjene maskiner, hvis dette sker. </p>
<p>Lytgobi indeholder lactose og natrium 
Dette lægemiddel indeholder lactose (findes i mælk eller mejeriprodukter). Kontakt lægen, før du 
tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter. 
Dette lægemiddel indeholder under 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det væsentlige 
natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take lytgobi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take lytgobi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Behandling med Lytgobi skal påbegyndes af en læge, som har erfaring med diagnosticering og 
behandling af galdegangskræft. Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets 
anvisning. Er du i tvivl, så spørg lægen eller apotekspersonalet.  </p>
<p>Den anbefalede dosis er 
5 tabletter Lytgobi 4 mg (20 mg futibatinib i alt) taget oralt en gang dagligt. Din læge vil justere dosen 
eller stoppe behandlingen, hvis det er nødvendigt. </p>
<p>Administration 
Synk tabletten hel med et glas vand på samme tidspunkt hver dag. Lytgobi kan tages med mad eller 
mellem måltider. Tabletterne skal synkes hele for at sikre, at den fulde dosis tages.  </p>
<p>Behandlingsvarighed 
Tag Lytgobi, så længe lægen har ordineret det. </p>
<p>Hvis du har taget for meget Lytgobi 
Fortæl det til lægen med det samme, hvis du har taget mere Lytgobi, end du skulle. </p>
<p>Hvis du har glemt at tage Lytgobi </p>
<ul>
<li>
<p>Hvis du glemmer en dosis Lytgobi i 12 timer eller mindre, skal du tage den glemte dosis, så snart 
du husker det. </p>
</li>
<li>
<p>Hvis du glemmer en dosis Lytgobi med mere end 12 timer, skal du springe den glemte dosis over. 
Tag den næste dosis på det sædvanlige tidspunkt. </p>
</li>
<li>
<p>Du må ikke tage en dobbelt dosis Lytgobi, hvis du oplever opkastning. Tag den næste dosis på det 
sædvanlige tidspunkt. </p>
</li>
<li>
<p>Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
</li>
</ul>
<p>Hvis du holder op med at tage Lytgobi 
Du må ikke holde op med at tage Lytgobi uden at tale med din læge, da det kan reducere 
behandlingens succes, hvis du stopper. </p>
<p>Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Hvis du har nogen af de alvorlige bivirkninger nedenfor, skal du fortælle det til lægen med det 
samme. Disse bivirkninger, som er anført nedenfor, er almindelige (kan påvirke op til 1 ud af personer). </p>
<ul>
<li>
<p>Migræne </p>
</li>
<li>
<p>Tarmobstruktion </p>
</li>
</ul>
<p>Andre bivirkninger<br />
Kontakt lægen, hvis du får bivirkninger. Disse kan forekomme med følgende hyppigheder: </p>
<p>Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer) </p>
<ul>
<li>
<p>høje eller lave fosfatniveauer set i blodprøver </p>
</li>
<li>
<p>lave natriumniveauer set i blodprøver </p>
</li>
<li>
<p>negle, der løsner sig fra neglelejet, dårlig negledannelse, ændring i neglenes farve </p>
</li>
<li>
<p>forstoppelse </p>
</li>
<li>
<p>diarré </p>
</li>
<li>
<p>mundtørhed </p>
</li>
<li>
<p>opkastning </p>
</li>
<li>
<p>mavesmerter </p>
</li>
<li>
<p>hårtab (alopeci) </p>
</li>
<li>
<p>en følelse af træthed eller svaghed </p>
</li>
<li>
<p>tør hud </p>
</li>
<li>
<p>høje niveauer af leverenzym set i blodprøver </p>
</li>
<li>
<p>kvalme </p>
</li>
<li>
<p>betændelse i slimhinden i munden (stomatitis)  </p>
</li>
<li>
<p>nedsat appetit </p>
</li>
<li>
<p>tørre øjne </p>
</li>
<li>
<p>rødme, hævelse, afskalning eller ømhed, hovedsageligt på hænder eller fødder (‘hånd-fod’ 
syndrom) </p>
</li>
<li>
<p>smagsforstyrrelser </p>
</li>
<li>
<p>muskelsmerter </p>
</li>
<li>
<p>ledsmerter </p>
</li>
</ul>
<p>Almindelige (kan påvirke 1 ud af 10 personer) </p>
<ul>
<li>Øjenproblemer, herunder betændelse i øjnene eller hornhinden (den forreste del af øjet), sløret 
syn, pludselig fremkomst af små mørke former, der bevæger sig i synsfeltet (flydere) og lysglimt i 
synsfeltet (fotopsi).  </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med lægen, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine 
pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale 
rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at 
fremskaffe mere information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store lytgobi"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store lytgobi"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Tag ikke lægemidlet efter den udløbsdato, der står på æsken og blister efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaring. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet eller skraldespanden.   </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lytgobi indeholder </p>
<ul>
<li>
<p>Aktivt stof: futibatinib<br />
Hver filmovertrukken tablet indeholder 4 mg futibatinib.  </p>
</li>
<li>
<p>Øvrige indholdsstoffer: 
Tabletkerne: majsstivelse, crospovidon, hydroxypropylcellulose, lactosemonohydrat, 
magnesiumstearat, mannitol, mikrokrystallinsk cellulose og natriumlaurilsulfat (se pkt. 2, 
“Lytgobi indeholder lactose og natrium")<br />
Filmovertrækning: hypromellose, macrogoler og titandioxid<br />
Lusteringsmiddel: magnesiumstearat </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Lytgobi 4 mg leveres som runde, hvide, filmovertrukne tabletter, præget på den ene side med “4MG" 
og “FBN" på den anden side. </p>
<p>Lytgobitabletter er pakket i et blisterkort, der er forseglet inde i et brev indeholdende en 7-dages 
forsyning som følger: </p>
<ul>
<li>
<p>20 mg daglig dosis: Hvert brev indeholder 35 tabletter (5 tabletter en gang dagligt).   </p>
</li>
<li>
<p>16 mg daglig dosis: Hvert brev indeholder 28 tabletter (4 tabletter en gang dagligt).   </p>
</li>
<li>
<p>12 mg daglig dosis: Hvert brev indeholder 21 tabletter (3 tabletter en gang dagligt).    </p>
</li>
</ul>
<p>Indehaver af markedsføringstilladelsen 
Taiho Pharma Netherlands B.V. 
Barbara Strozzilaan 1083HN Amsterdam 
Holland </p>
<p>Fremstiller 
PCI Pharma Services (Millmount Healthcare Limited) 
Block 7, City North Business Campus 
Stamullen, Co. Meath, K32 YDIrland </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ} 
Dette lægemiddel er godkendt under “betingede omstændigheder".<br />
Det betyder, at der forventes yderligere dokumentation for lægemidlet. 
Det Europæiske Lægemiddelagentur vil mindst en gang om året vurdere nye oplysninger om 
lægemidlet, og denne indlægsseddel vil om nødvendigt blive ajourført. </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs </p>
<p>hjemmeside: http://www.ema.europa.eu. </p>
<p>Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-dbc2060ee6f62aba124d52b5666f8915
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for lytgobi Package Leaflet for language en"
Description: "ePI document Bundle for lytgobi Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-dbc2060ee6f62aba124d52b5666f8915"
* entry[0].resource = composition-en-dbc2060ee6f62aba124d52b5666f8915

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpdbc2060ee6f62aba124d52b5666f8915"
* entry[=].resource = mpdbc2060ee6f62aba124d52b5666f8915
                            
                    
Instance: bundlepackageleaflet-da-dbc2060ee6f62aba124d52b5666f8915
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for lytgobi Package Leaflet for language da"
Description: "ePI document Bundle for lytgobi Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-dbc2060ee6f62aba124d52b5666f8915"
* entry[0].resource = composition-da-dbc2060ee6f62aba124d52b5666f8915

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpdbc2060ee6f62aba124d52b5666f8915"
* entry[=].resource = mpdbc2060ee6f62aba124d52b5666f8915
                            
                    



Instance: mpdbc2060ee6f62aba124d52b5666f8915
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product lytgobi"
Description: "lytgobi"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Lytgobi 4 mg tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "lytgobi"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: dbc2060ee6f62aba124d52b5666f8915ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "lytgobi"

* status = #current
* mode = #working

* title = "List of all ePIs associated with lytgobi"

* subject = Reference(mp78f306f1e92f048feb21539cfb100a4b)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#lytgobi "lytgobi"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-dbc2060ee6f62aba124d52b5666f8915) // lytgobi en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-dbc2060ee6f62aba124d52b5666f8915) // lytgobi da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-dbc2060ee6f62aba124d52b5666f8915
InstanceOf: List

* insert dbc2060ee6f62aba124d52b5666f8915ListRuleset
    